Sichuan Goldstone Asia Pharmaceutical Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 617.04 million compared to CNY 455.17 million a year ago. Revenue was CNY 633.73 million compared to CNY 479.43 million a year ago.

Net income was CNY 155.73 million compared to CNY 82.2 million a year ago. Basic earnings per share from continuing operations was CNY 0.3876 compared to CNY 0.2046 a year ago. Diluted earnings per share from continuing operations was CNY 0.3876 compared to CNY 0.2046 a year ago.